BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Rhea-AI Summary

BioCardia (NASDAQ:BCDA), a company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, will host its Q2 2025 earnings conference call on August 11, 2025 at 4:30 PM ET.

The company will provide a corporate update and discuss financial results for the quarter ended June 30, 2025. The call will include management remarks followed by a Q&A session. Participants can join through a dial-in number after registration or via webcast.

News Market Reaction

-5.52%

1 alert

-5.52% News Effect

On the day this news was published, BCDA declined 5.52%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia^®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to https://dpregister.com/sreg/10201553/ff96e5f036. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZDm6XgM2.

A webcast replay of the call will be available approximately one hour after the end of the call at the above links. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 7650783.

About BioCardia^®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP^® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph^® vascular navigation product platforms. For more information visit www.biocardia.com.

MEDIA CONTACT:
Miranda Peto, Marketing / Investor Relations
mpeto@biocardia.com
(650) 226-0120

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120

FAQ

When is BioCardia's (BCDA) Q2 2025 earnings call?

BioCardia's Q2 2025 earnings call is scheduled for Monday, August 11, 2025 at 4:30 PM ET.

How can investors join BioCardia's Q2 2025 earnings call?

Investors can join by registering at dpregister.com for a dial-in number, calling directly (U.S.: 1-833-316-0559, International: 1-412-317-5730), or watching the webcast through the company's provided link.

What will be discussed in BioCardia's Q2 2025 earnings call?

The call will include a corporate update and discussion of financial results for Q2 2025 ended June 30, followed by a Q&A session.

What is BioCardia's (BCDA) main business focus?

BioCardia is a developer of cellular and cell-derived therapeutics focused on treating cardiovascular and pulmonary diseases.